ERIS vs GLENMARK: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. ERIS LIFESCIENCES shows a lower P/E, a higher ROE and a higher dividend yield, while GLENMARK PHARMACEUTICALS shows faster revenue growth, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ERIS leads 6; GLENMARK leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ERIS | GLENMARK |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ERIS | GLENMARK |
|---|---|---|
| Live Price | ₹1,321.7 | ₹2,437.2 |
| Day Change | 1.4% | -0.89% |
| Volume | 69,111 | 4.13 L |
| 52-Week High | ₹1,797.6 | ₹2,537.6 |
| 52-Week Low | ₹1,200 | ₹1,792.6 |
| Distance from 52W High | -26.47% | -3.96% |
Valuation
| Metric | ERIS | GLENMARK |
|---|---|---|
| Market Cap | ₹18,299 Cr | ₹68,490 Cr |
| P/E Ratio | 28.56x | 46.23x |
| P/B Ratio | 4.74x | 6.58x |
| EPS | ₹3.49 | ₹26.07 |
| Book Value | ₹281.12 | ₹372.49 |
| Dividend Yield | 0.55% | 0.21% |
Growth
| Metric | ERIS | GLENMARK |
|---|---|---|
| Revenue Growth (TTM YoY) | 7.1% | 14.3% |
| EPS Growth (TTM YoY) | 200% | 6,575% |
| Qtr Sales Growth | -49.16% | -39.41% |
| Qtr Profit Growth | -66.3% | 52.36% |
Profitability & Leverage
| Metric | ERIS | GLENMARK |
|---|---|---|
| ROE | 16.62% | 12.96% |
| ROCE | 13.51% | 18.25% |
| Net Margin | 19.89% | 8.15% |
| Operating Margin | 26.56% | 12.92% |
| Debt to Equity | 0.59x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ERIS | GLENMARK |
|---|---|---|
| Promoter Holding | 54.14%▲ 0.22 pp | 46.65% |
| FII Holding | 5.75%▼ 0.64 pp | 20.89%▲ 0.55 pp |
| DII Holding | 20.72%▲ 0.37 pp | 18.6%▼ 0.69 pp |
| Public Holding | 19.4%▲ 0.07 pp | 13.81%▲ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ERIS LIFESCIENCES and GLENMARK PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.